{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:40:21Z","timestamp":1790030421741,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,4,5]],"date-time":"2016-04-05T00:00:00Z","timestamp":1459814400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005570","name":"Takeda Pharmaceuticals North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H Lundbeck A\/S","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s40262-016-0389-0","type":"journal-article","created":{"date-parts":[[2016,4,5]],"date-time":"2016-04-05T09:51:31Z","timestamp":1459849891000},"page":"1115-1127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium"],"prefix":"10.1007","volume":"55","author":[{"given":"Grace","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Nomikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Affinito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,5]]},"reference":[{"issue":"10","key":"389_CR1","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1185\/03007995.2012.725035","volume":"28","author":"DS Baldwin","year":"2012","unstructured":"Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012;28(10):1717\u201324.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"389_CR2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/YIC.0000000000000081","volume":"30","author":"PL Jacobsen","year":"2015","unstructured":"Jacobsen PL, Harper L, Chrones L, Chan S, Mahableshwarkar AR. Safety and tolerability of vortioxetine (15 and 20 mg) in subjects with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2015;30(5):255\u201364.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"389_CR3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.14r09164","volume":"76","author":"J Zhang","year":"2014","unstructured":"Zhang J, Mathis MV, Sellers JW, Kordzakhia G, Jackson AJ, Dow A, et al. The US Food and Drug Administration\u2019s perspective on the new antidepressant vortioxetine. J Clin Psychiatry. 2014;76(1):8\u201314.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"389_CR4","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","volume":"54","author":"B Bang-Andersen","year":"2011","unstructured":"Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54(9):3206\u201321.","journal-title":"J Med Chem"},{"issue":"Suppl 1","key":"389_CR5","first-page":"47","volume":"16","author":"L Westrich","year":"2012","unstructured":"Westrich L, Pehrson A, Zhong H, Nielsen SM, Frederiksen K, Stensbol TB, et al. In vitro and in vivo effects for the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract. 2012;16(Suppl 1):47.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"3","key":"389_CR6","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1124\/jpet.111.189068","volume":"340","author":"A Mork","year":"2012","unstructured":"Mork A, Pehrson A, Brennum LT, Moller NS, Zhong H, Lassen AB, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012;340(3):666\u201375.","journal-title":"J Pharmacol Exp Ther"},{"key":"389_CR7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","volume":"145","author":"C Sanchez","year":"2015","unstructured":"Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43\u201357.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"389_CR8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.euroneuro.2012.04.006","volume":"23","author":"AL Pehrson","year":"2013","unstructured":"Pehrson AL, Cremers T, Betry C, van der Hart MG, Jorgensen L, Madsen M, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters: a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol. 2013;23(2):133\u201345.","journal-title":"Eur Neuropsychopharmacol"},{"key":"389_CR9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1742-7843.2012.00886.x","volume":"111","author":"J Areberg","year":"2012","unstructured":"Areberg J, Sogaard B, Hojer AM. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young subjects. Basic Clin Pharmacol Toxicol. 2012;111:198\u2013205.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"389_CR10","volume-title":"Brintellix [package insert]","author":"Takeda Pharmaceuticals America, Inc.","year":"2014","unstructured":"Takeda Pharmaceuticals America, Inc. Brintellix [package insert]. Deerfield (IL): Takeda Pharmaceuticals America, Inc; 2014."},{"issue":"7","key":"389_CR11","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1124\/dmd.112.044610","volume":"40","author":"MG Hvenegaard","year":"2012","unstructured":"Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012;40(7):1357\u201364.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"389_CR12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcph.456","volume":"55","author":"G Chen","year":"2015","unstructured":"Chen G, Zhang W, Serenko M. Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. J Clin Pharmacol. 2015;55(6):671\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"389_CR13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1176\/appi.ajp.2012.12010112","volume":"170","author":"HM Pettinati","year":"2013","unstructured":"Pettinati HM, O\u2019Brien CP, Dundon WD. Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry. 2013;170(1):23\u201330.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"389_CR14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0404.2008.01004.x","volume":"118","author":"J Riss","year":"2008","unstructured":"Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008;118(2):69\u201386.","journal-title":"Acta Neurol Scand"},{"key":"389_CR15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-3-540-74806-9_16","volume":"182","author":"KT Olkkola","year":"2008","unstructured":"Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;182:335\u201360.","journal-title":"Handb Exp Pharmacol"},{"key":"389_CR16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jad.2014.05.053","volume":"168","author":"JC Nelson","year":"2014","unstructured":"Nelson JC, Baumann P, Delucchi K, Joffe R, Katona C. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord. 2014;168:269\u201375.","journal-title":"J Affect Disord"},{"issue":"5","key":"389_CR17","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.jcp.0000237944.57893.28","volume":"26","author":"D Thai","year":"2006","unstructured":"Thai D, Dyer JE, Benowitz NL, Haller CA. Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Psychopharmacol. 2006;26(5):524\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"389_CR18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40261-013-0117-6","volume":"33","author":"G Chen","year":"2013","unstructured":"Chen G, Lee R, Hojer AM, Buchbjerg JK, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33(10):727\u201336.","journal-title":"Clin Drug Investig"},{"issue":"Suppl 1","key":"389_CR19","first-page":"7","volume":"4","author":"D Allen","year":"1989","unstructured":"Allen D, Lader M. Interactions of alcohol with amitriptyline, fluoxetine and placebo in normal subjects. Int Clin Psychopharmacol. 1989;4(Suppl 1):7\u201314.","journal-title":"Int Clin Psychopharmacol"},{"key":"389_CR20","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/clpt.1985.107","volume":"37","author":"L Lemberger","year":"1985","unstructured":"Lemberger L, Rowe H, Bergstrom FG, Farid KZ, Enas GG. Effect of fluoxetine on psychomotor performance, physiologic response, and kinetics of ethanol. Clin Pharmacol Ther. 1985;37:658\u201364.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"389_CR21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00606656","volume":"31","author":"M Lader","year":"1986","unstructured":"Lader M, Melhuish A, Frcka G, Fredicson O, Christensen V. The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects. Eur J Clin Pharmacol. 1986;31(2):183\u201390.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"389_CR22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2710.2006.00745.x","volume":"31","author":"J Adan-Manes","year":"2006","unstructured":"Adan-Manes J, Novalbos J, Lopez-Rodriguez R, Ayuso-Mateos JL, Abad-Santos F. Lithium and venlafaxine interaction: a case of serotonin syndrome. J Clin Pharm Ther. 2006;31(4):397\u2013400.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"389_CR23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/070674370104600306","volume":"46","author":"AK Dalfen","year":"2001","unstructured":"Dalfen AK, Stewart DE. Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors? Can J Psychiatry. 2001;46(3):258\u201363.","journal-title":"Can J Psychiatry"},{"issue":"4","key":"389_CR24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00004850-200015040-00002","volume":"15","author":"CJ Hawley","year":"2000","unstructured":"Hawley CJ, Loughlin PJ, Quick SJ, Gale TM, Sivakumaran T, Hayes J, et al. Efficacy, safety and tolerability of combined administration of lithium and selective serotonin reuptake inhibitors: a review of the current evidence. Int Clin Psychopharmacol. 2000;15(4):197\u2013206.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"389_CR25","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0022-3565(25)23377-8","volume":"239","author":"E Bodd","year":"1986","unstructured":"Bodd E, Gadeholt G, Christensson PI, Mrland J. Mechanisms behind the inhibitory effect of ethanol on the conjucation of morphine in rat hepatocytes. J Pharmacol Exp Ther. 1986;239(3):887\u201390.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"389_CR26","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/hep.20673","volume":"41","author":"S Liangpunsakul","year":"2005","unstructured":"Liangpunsakul S, Kolwanker D, Pinto A, Gorski C, Hall SD, Chalansani N. Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics. Hepatology. 2005;41(5):1144\u201350.","journal-title":"Hepatology"},{"key":"389_CR27","first-page":"760","volume":"46","author":"D Djordejevic","year":"1998","unstructured":"Djordejevic D, Nikolic J, Stafanovic V. Ethanol interactions with other cytochrome P450 substrates including drugs, xenobiotics, and carcinogens. Pathol Biol (Paris). 1998;46:760\u201370.","journal-title":"Pathol Biol (Paris)"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0389-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-016-0389-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0389-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T04:53:32Z","timestamp":1748840012000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-016-0389-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,5]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1007\/s40262-016-0389-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,5]]}}}